Reversal of Complete Heart Block With Aminophylline in Inferior Wall Myocardial Infarction Patients

Last updated: May 20, 2025
Sponsor: National Institute of Cardiovascular Diseases, Pakistan
Overall Status: Trial Not Available

Phase

4

Condition

Hypercholesterolemia

Circulation Disorders

Angina

Treatment

Aminophylline Injection

Clinical Study ID

NCT05666219
ERC-32/2022
  • Ages > 18
  • All Genders

Study Summary

In this study, the investigator will evaluate the rate of reversal of complete heart block with aminophylline in atropine resistant patients with inferior wall myocardial infarction (MI)

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult patients admitted with recent acute inferior wall myocardial infarction (MI)

  • Hemodynamically stable blood pressure

  • Complete heart block with Narrow QRS < 120 ms and ventricular rate >40/minpersisting for at least 6 hours, resistant to atropine

  • Temporary pacemaker (TPM) already placed

  • Patient asymptomatic with a mean arterial pressure of greater than 65 mmHg with TPMrate placed at 40/min

Exclusion

Exclusion Criteria:

  • Patients with cardiogenic shock

  • Patients with preexisting permanent pacemaker and Implantable CardioverterDefibrillator (ICD).

  • Patients with a prior history of AV block

  • Drugs with dromotropic effects (beta blocker, calcium channel blocker, inotropes)

  • Known liver disease (cirrhosis, hepatitis)

  • Hypothyroidism

  • Unable to consent

Study Design

Treatment Group(s): 1
Primary Treatment: Aminophylline Injection
Phase: 4
Study Start date:
December 19, 2022
Estimated Completion Date:
January 17, 2025

Study Description

Administration of Aminophylline can result in reversal of complete heart block in a significant number of atropine resistant patients with inferior wall MI. Hence, in this study our primary aim is to evaluate the rate of reversal of complete heart block with aminophylline in atropine resistant patients with inferior wall MI.